Displaying drugs 11951 - 11975 of 12723 in total
Coramitug
Investigational
Lexacalcitol
Lexacalcitol is a solid. This compound belongs to the vitamin D and derivatives class of chemicals. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. It is known to target the vitamin D3 receptor.
Experimental
Matched Description: … Lexacalcitol is a solid. This compound belongs to the vitamin D and derivatives class of chemicals. ... These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. …
EP-2104R
EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.
Investigational
Matched Description: … EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. …
ISIS 14803
ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
Investigational
Matched Description: … ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus ... (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits …
Tiletamine
This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.
Vet approved
Matched Description: … This drug is a dissociative anesthetic agent that falls under the drug category of _NMDA receptor antagonists …
Garadacimab
Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).
Investigational
Matched Description: … Chemotherapy Through a PICC Line). ... and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive ... Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy …
Epratuzumab
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
Investigational
Matched Description: … Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 ... This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune …
Cimicoxib
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action ... Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …
RI 624
RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Investigational
Matched Description: … of acute and chronic pain. ... RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator …
SNX-5422
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Description: … breakthrough therapy with broad applicability across a wide range of cancers. ... SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. ... As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a …
Tricaine
Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish. It is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.
Vet approved
Matched Description: … Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of …
Naquotinib
Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor (EGFR) Mutations, among others.
Investigational
Matched Description: … Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer …
S-3304
S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.
Investigational
Matched Description: … S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung …
Sulfaisodimidine
Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .
Experimental
Matched Description: … Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of …
EGT-201
EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.
Investigational
Matched Description: … EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of …
RPI-MN
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
Matched Description: … RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. ... developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of …
Triciribine phosphate
Investigational
Beta-(1,3)-D glucan
Investigational
Barecetamab
Investigational
LJ-2698
Investigational
Osemitamab
Investigational
Nemonapride
Investigational
GPI-1485
GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands.
In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.
GPI 1485 is being studied in phase 2 clinical trials for the treatment...
Investigational
Matched Description: … GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ... GPI 1485 is being studied in phase 2 clinical trials for the treatment of Parkinson's disease and post-prostatectomy …
MKC1106-PP
MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. The plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and PSMA. MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a...
Investigational
Matched Description: … MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides ... The plasmid portion is a recombinant plasmid expressing segments of the 2 target antigens, PRAME and ... MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component …
Displaying drugs 11951 - 11975 of 12723 in total